JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


First published online September 15, 2008, 10.2967/jnumed.108.052803
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jnumed.108.052803v1
49/10/1573    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Tait, J. F.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tait, J. F.
Journal of Nuclear Medicine Vol. 49 No. 10 1573-1576
© 2008 by Society of Nuclear Medicine

doi: 10.2967/jnumed.108.052803

Focus on Molecular Imaging

Imaging of Apoptosis

Jonathan F. Tait

University of Washington
Seattle, Washington

Correspondence: For correspondence or reprints contact: Jonathan Tait, Department of Laboratory Medicine, University of Washington, Box 357110, Seattle, WA 98195-7110. E-mail: tait{at}u.washington.edu

ABSTRACT

Cells can die by several pathways, such as accidental death, apoptosis, autophagy, pyroptosis, and oncosis. These are important in normal physiology and many disease states, such as cancer and cardiovascular disease. Specific biochemical changes occur in cells undergoing apoptosis that provide potential targets for molecular imaging agents. Several of these molecular steps have been evaluated to date, including phosphatidylserine exposure at the extracellular face of the plasma membrane, detected by proteins such as annexin V; caspase activation in the intracellular compartment, detected by labeled enzyme substrates or inhibitors; and mitochondrial membrane potential collapse, detected by reduced levels of phosphonium cations that normally accumulate in healthy mitochondria. Phase I clinical trials have been performed with 1 of these agents, annexin V. Future work will likely include development of new agents that detect targets not exploited by current agents, translational research on the significance of imaging the different forms of cell death, and further improvements in the techniques for labeling existing agents to improve sensitivity and reduce nonspecific background.

Key Words: molecular biology • molecular imaging • radiochemistry • apoptosis • imaging • annexins

FOOTNOTES

COPYRIGHT © 2008 by the Society of Nuclear Medicine, Inc.


Related articles in JNM:

This Month in JNM

JNM 2008 49: 11A-12A. [Full Text]  






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2008 by the Society of Nuclear Medicine.